Millions of Americans taking blockbuster weight-loss drugs like Ozempic and Mounjaro may be predisposed to either dramatic results or complete failure, according to a sweeping genetic study of nearly 28,000 patients.
Published today in Nature, the research revealed genetic variants in the GLP1R and GIPR receptor genes that predict both the efficacy and side effects of these popular weight-loss medications. The findings challenge the pharmaceutical industry's one-size-fits-all approach, suggesting millions of patients could be genetically predisposed to poor outcomes.
Researchers at 23andMe analyzed genetic data from participants who reported using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). The results were stark: a GLP1R gene variant was associated with an additional 0.76 kilograms of weight loss per copy of the protective allele. More significantly, variants in both GLP1R and GIPR predicted who would experience treatment-limiting nausea and vomiting.
The study population reflected real-world usage patterns: 82.4% female, median age 52, with a starting BMI of 35.1. Participants had been on treatment for a median of 8.3 months and lost an average of 11.7% of their pre-treatment weight. But the variation was enormous — some achieved over 25% weight loss while others gained weight.
For tirzepatide users specifically, the GIPR gene variant created an additional layer of complexity. Since tirzepatide targets both GLP-1 and GIP receptors (hence its superior efficacy), genetic variations in GIPR influenced both effectiveness and side effects in ways that don't apply to semaglutide users.
- GLP1R — Controls how cells respond to GLP-1 hormone signals for appetite suppression and insulin release
- GIPR — Regulates response to GIP hormone, affecting both metabolism and gastrointestinal side effects
- Combined effect — Genetic variants can predict both drug efficacy and tolerability with statistical significance
The research team, led by scientists at 23andMe, surveyed participants in August 2024 and compiled responses through August 2025. The genetic analysis revealed that drug response isn't just about lifestyle factors or pre-existing conditions — it's written in the DNA of the drug targets themselves.
Beyond genetics, the study confirmed several patterns from clinical trials. Women responded better than men (12.2% vs 10.0% BMI reduction), and people of European ancestry showed greater weight loss than other groups. Tirzepatide consistently outperformed semaglutide, with median BMI reductions of 4.75 vs 3.71 kg/m².
These findings "suggest genetic differences may contribute to why people respond differently to weight-loss jabs," The Guardian reports, potentially reshaping how doctors prescribe these medications and how patients set expectations.
The research arrives as the $6 billion GLP-1 market faces growing scrutiny over variable outcomes. In clinical trials, 10-15% of patients are classified as "non-responders" because they fail to lose at least 5% of their body weight. The new genetic data suggests this isn't random chance — it's predictable biology.
For the pharmaceutical industry, genetic stratification represents both opportunity and threat. Companies could develop companion diagnostics to identify ideal candidates, potentially improving success rates and reducing side effects. But they could also face pressure to develop alternative treatments for patients with unfavorable genetics, fragmenting what has been a blockbuster market.
The study's scope — nearly 28,000 participants across multiple ancestries — provides the statistical power needed to influence clinical practice. According to The Washington Post, "some people experience profound weight loss; others barely see the scale budge," and this research finally explains why at the molecular level.
As genetic testing costs continue to fall, the implications for obesity treatment are clear. The technology to identify favorable genetic variants already exists. The remaining question is whether insurers will use this information to expand access for good responders or restrict coverage for predicted non-responders.
This research represents a pivotal moment for personalized obesity medicine. Future studies will likely identify additional genetic factors, refine prediction models, and potentially guide the development of next-generation treatments tailored to specific genetic profiles. For now, millions of patients have a clearer picture of why their expensive medications work — or don't.
